Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...
PRINCETON, N.J., Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...
2025 at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com.
conference, taking place from January 25-29, 2025, in San Diego, California. The bit.bio team will be at Booth #851, present multiple poster sessions and host a panel discussion with industry experts, ...
Hosted on MSN4d
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific ConferencesPHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its ...
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that its Chief Executive Officer, Maria Maccecchini, Ph.D., will ...
Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Royale Room and will be available to participate in ...
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq ... today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback